Beyond cancer: The potential application of CD47-based therapy in non-cancer diseases
CD47 is an immune checkpoint widely regarded as a ‘don't eat me’ signal. CD47-based anti-cancer therapy has received considerable attention, with a significant number of clinical trials conducted. While anti-cancer therapies based on CD47 remain a focal point of interest among researchers, it i...
Saved in:
| Main Authors: | Wei-Qing Deng, Zi-Han Ye, Zhenghai Tang, Xiao-Lei Zhang, Jin-Jian Lu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383524004519 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma
by: Liping Qin, et al.
Published: (2024-12-01) -
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01) -
Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression
by: Oanh T. P. Nguyen, et al.
Published: (2024-12-01) -
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy
by: Mithunah Krishnamoorthy, et al.
Published: (2025-02-01) -
Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
by: Jian‐Hua Wang, et al.
Published: (2019-03-01)